Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: Development of cetuximab and panitumumab

Journal of Clinical Pharmacology

Volumn 52, Issue 2, 2012, Pages 128-155

  You, Benoit ^a   Chen, Eric X ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

cetuximab; colorectal cancer; epidermal growth factor receptor; monoclonal antibody; panitumumab

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CONATUMUMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; IMATINIB; IMPRIME PGG; IRINOTECAN; MONOCLONAL ANTIBODY; MOTESANIB; OXALIPLATIN; PANITUMUMAB; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RILOTUMUMAB; SUNITINIB; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR;

ACNE; ALLERGY; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CHEST TIGHTNESS; COLORECTAL CANCER; DIARRHEA; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG TARGETING; DRY SKIN; DYSPNEA; EDEMA; EPIGLOTTIS TOXICITY; FATIGUE; HUMAN; HYPOMAGNESEMIA; HYPOTENSION; LYMPHOCYTOPENIA; MENINGITIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; RASH; REVIEW; SKIN TOXICITY; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84856614470     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010395940     Document Type: Review

References (148)

1. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 ; 27: 3677-3683
2. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res. 2002 ; 8: 994-1003 (Pubitemid 34517632)
3. Peeters M, Price T, Van Laethem JL. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?. Oncologist. 2009 ; 14: 29-39
4. FDA approval for cetuximab. National Cancer Institute Web site. http://www.cancer.gov/cancertopics/druginfo/fda-cetuximab. Accessed January 10, 2011.
5. FDA approval for panitumumab. National Cancer Institute Web site. http://www.cancer.gov/cancertopics/druginfo/fda-panitumumab. Accessed January 10, 2011.
6. Vectibix. European Medicines Agency Web site. http://www.emea.europa.eu/ humandocs/Humans/EPAR/vectibix/vectibix.htm. Accessed January 10, 2011.
7. Erbitux. European Medicines Agency Web site. http://www.emea.europa.eu/ humandocs/humans/EPAR/erbitux/erbitux.htm. Accessed January 10, 2011.
8. Talavera A, Friemann R, Gomez-Puerta S, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009 ; 69: 5851-5859
9. Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev. 2009 ; 35: 354-363
10. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer. 2001 ; 37: S16 - S22
11. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004 ; 22: 1646-1654 (Pubitemid 41079803)
12. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000 ; 18: 904-914 (Pubitemid 30106623)
13. Humblet H, Peeters M, Bleiberg H, et al. An open-label, phase I study of cetuximab to assess the safety, efficacy and pharmacokinetics (PK) of different cetuximab regimens in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC). Proceedings from the American Society of Clinical Oncology Annual Meeting ; ;..
14. Tan AR, Moore DF, Hidalgo M, et al. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res. 2006 ; 12: 6517-6522 (Pubitemid 44799726)
15. Fracasso PM, Burris H, Arquette MA, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res. 2007 ; 13: 986-993 (Pubitemid 46340377)
16. Ho C, Sangha R, Beckett L, et al. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Invest New Drugs. 2010 ;:
17. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001 ; 7: 1204-1213 (Pubitemid 32708671)
18. Delbaldo C, Pierga JY, Dieras V, et al. Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur J Cancer. 2005 ; 41: 1739-1745 (Pubitemid 41132635)
19. Arnold D, Hohler T, Dittrich C, et al. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol. 2008 ; 19: 1442-1449
20. Raoul JL, Van Laethem JL, Peeters M, et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer. 2009 ; 9: 112
21. Trarbach T, Schuette K, Stoehlmacher J, et al. Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
22. Guarino MJ, Schneider CJ, Hosford MA, et al. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist. 2009 ; 14: 119-124
23. Lin CC, Calvo E, Papadopoulos KP, et al. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009 ; 63: 1065-1071
24. Sharma S, Reid T, Hoosen S, et al. Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
25. Folprecht G, Schuette K, Stoehlmacher J, Goekkurt E, Trarbach T. Cetuximab and FOLFOXIRI: dose-escalation study in previously untreated patients with metastatic colorectal cancer. Proceedings of the 2010 Gastrointestinal Cancers Symposium ; ;..
26. Kopetz S, Wolff RA, Eng C, et al. Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. Proceedings of the 2010 Gastrointestinal Cancers Symposium ; ;..
27. El-Khoueiry AB, Iqbal S, Feit K, et al. A phase I study of E7820 in combination with Cetuximab in patients (pts) with advanced solid tumors. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
28. Tamayo MB, Cornelio GH, Bautista JB, et al. A phase Ib/II, dose-escalating, safety, and efficacy study of imprime PGG and cetuximab in patients with advanced colorectal cancer (CRC). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
29. Yee L, Burris A, Kozloff M, et al. Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): preliminary results. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
30. Goff LW, Chan E, Backlund DC, et al. A phase I clinical and biological evaluation of combined epidermal growth factor receptor (EGFR) blockade with erlotinib (E) and cetuximab (C) in patients (pts) with advanced cancer. Proceedings of the 2010 Gastrointestinal Cancers Symposium ; ;..
31. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004 ; 22: 1201-1208 (Pubitemid 41079832)
32. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006 ; 24: 4914-4921 (Pubitemid 46630920)
33. Wierzbicki R, Jonker DJ, Moore MJ, et al. A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Invest New Drugs. 2009 ;:
34. Vincenzi B, Santini D, Rabitti C, et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer. 2006 ; 94: 792-797
35. Mathias C, Buzaid A, Perazzo F, et al. Phase II study of cetuximab with irinotecan in patients with epidermal growth factor (EGFR)-expressing metastatic colorectal cancer (mCRC): LABEL preliminary data. Proceedings of the 2007 Gastrointestinal Cancers Symposium ; ;..
36. Tahara M, Shirao K, Boku N, et al. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. Jpn J Clin Oncol. 2008 ; 38: 762-769
37. Lim R, Sun Y, Im S, et al. Cetuximab in combination with irinotecan in the treatment of patients (pts) with metastatic colorectal carcinoma (mCRC) refractory to irinotecan: Preliminary data from the ELSIE study. Proceedings of the 2008 Gastrointestinal Cancers Symposium ; ;..
38. Gamucci T, Nelli F, Cianci G, et al. A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities. Clin Colorectal Cancer. 2008 ; 7: 273-279
39. Wilke H, Glynne-Jones R, Thaler J, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL study. J Clin Oncol. 2008 ; 26: 5335-5343
40. Shitara K, Yokota T, Takahari D, et al. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pretreated metastatic colorectal cancer harboring wild-type KRAS. Invest New Drugs. 2010 ; 40: 699-701
41. Colucci G, Giuliani F, Mattioli R, et al. FOLFOX-4 + cetuximab in untreated patients with advanced colorectal cancer. A phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2402). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
42. Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007 ; 25: 5225-5232 (Pubitemid 350232254)
43. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
44. Borner M, Koeberle D, Von Moos R, et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol. 2008 ; 19: 1288-1292 (Pubitemid 351911959)
45. Barroso S, Sanches E, Ferreira M, et al. Efficacy and safety of cetuximab, oxaliplatin, and capecitabine as first-line therapy for metastatic colorectal cancer (mCRC): results of a phase II study. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
46. Souglakos J, Kalykaki A, Vamvakas L, et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol. 2007 ; 18: 305-310 (Pubitemid 46323098)
47. Petrovic Z. Capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatatic colorectal carcinoma who progressed after oxaliplatin-based chemotherapy. Proceedings of the 2008 ESMO Congress ; ;..
48. Rosenberg A, Loehrer P, Needle M, et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
49. Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol. 2006 ; 17: 450-456 (Pubitemid 43329582)
50. Cartwright T, Kuefler P, Cohn A, et al. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. Clin Colorectal Cancer. 2008 ; 7: 390-397
51. Koo DH, Lee JL, Kim TW, et al. A phase II study of cetuximab (erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. J Korean Med Sci. 2007 ; 22: S98 - S103
52. Folprecht G, Gruenberger T, Hartmann J, et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study). Proceedings of the 2009 Gastrointestinal Cancers Symposium ; ;..
53. Garufi C, Torsello A, Tumolo S, et al. POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
54. Ychou M, Desseigne F, Thezenas S, et al. Preliminary results of a multicentre phase II trial evaluating cetuximab in combination with FOLFIRINOX (LV5FU + Irinotecan + Oxaliplatin) as first line treatment of metastatic colorectal cancer (mCRC) patients. Proceedings of the 2009 Gastrointestinal Cancers Symposium ; ;..
55. Boccia RV, Cosgriff TM, Headley DL, Badarinath S, Dakhil SR. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2010 ; 9: 102-107
56. Moosmann M, Fisher Von Weikersthal L, Vehling-Kaiser U, et al. Final analysis of the randomized trial of the German AIO CRC study group: cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
57. Ocvirk J, Brodowicz T, Wrba F, et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol. 2010 ; 16: 3133-3143
58. Grávalos C, Rivera F, Massutí B, et al. Cetuximab and capecitabine as first-line treatment for elderly patients (pts) with metastatic colorectal cancer (mCRC): preliminary results of TTD trial. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
59. Rozzi A, Corona M, Nardoni C, Petricola F, Restuccia M, Lanzetta G. Capecotabome plus cetuximab as second line chemotherapy in elderly patients with metastatic colorectal cancer: results of a phase II study. Proceedings of the 2008 World Congress on Gastrointestinal Cancer ; ;..
60. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007 ; 25: 4557-4561 (Pubitemid 350035312)
61. Segal N, Reidy-Lagunes D, Capanu M, et al. Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
62. Spigel D, Waterhouse D, Shipley D, et al. Phase II trial of modified FOLFOX6, bevacizumab, and cetuximab in first-line metastatic colorectal cancer treatment. Proceedings of the 2009 Gastrointestinal Cancers Symposium ; ;..
63. Martin-Martorell P, Rosello S, Rodriguez-Braun E, Chirivella I, Bosch A, Cervantes A. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer. 2008 ; 99: 455-458
64. Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol. 2008 ; 19: 1141-1145 (Pubitemid 351796340)
65. Carneiro B, Bahary N, Lembersky B, et al. Phase II study of biweekly cetuximab (C) and irinotecan (I) as a second-line regimen for metastatic colorectal cancer (mCRC). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
66. Yuan Y, Ma H, Cohen D, et al. Activity and tolerance of biweekly CapeOx-Cetuximab in first-line therapy of metastatic colorectal cancer (mCRC) and K-ras influences. Proceedings of the 2009 Gastrointestinal Cancers Symposium ; ;..
67. Sobrero A, Bennicelli E, Pessino A, et al. Phase II trial of imatinib, bevacizumab and cetuximab plus modified FOLFOX-6 in advanced untreated colorectal cancer. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
68. Pfeiffer P, Joergensen T, Jensen B, et al. Addition of bevacizumab or sunitinib to biweekly cetuximab and irinotecan as salvage therapy in patients with metastatic colorectal cancer after failure to CetIri. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
69. Tabernero J, Ciardiello F, Rivera F, et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol. 2009 ;:
70. Schueller J, Czejka M, Kiss A, et al. Influence of cetuximab applied as biweekly infusion on the plasma disposition of CPT 11 and its metabolites in advanced colorectal cancer. Proceedings of the 2009 ECCO-ESMO Congress ; ;..
71. Tabernero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?. Oncologist. 2008 ; 13: 113-119 (Pubitemid 351342574)
72. Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
73. Maughan T. Changes to toxicity with the addition of cetuximab or substitution of capecitabine in FOLFOX: prelimimary safety report for the frist 804 patients from the MRC COIN trial. Proceedings of the 2007 World Congress on Gastrointestinal Cancer ; ;..
74. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 ; 360: 1408-1417
75. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009 ; 360: 563-572
76. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004 ; 351: 337-345 (Pubitemid 38944402)
77. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007 ; 357: 2040-2048 (Pubitemid 350106711)
78. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 ; 26: 2311-2319
79. Maughan T, Adams R, Smith C, et al. Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). Proceedings of the 2009 ECCO-ESMO Congress ; ;..
80. Khazaeli M, LoBuglio A, Falcey J, Paulter V, Fetzer M, Waksal H. Low immunogenicity of a chimeric monoclonal antibody (MoAb), IMC-C225, used to treat epidermal growth factor receptor-positive tumors. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
81. Liu L, Cao Y, Tan A, Liao C, Gao F. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemother Pharmacol. 2010 ; 65: 849-861
82. Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol. 2008 ; 47: 9-19
83. Yamada Y, Tamura T, Shirao K, et al. Safety and pharmacokinetics (PK) of panitumumab in Japanese patients (pts) with advanced solid malignancies. Proceedings of the 2007 Gastrointestinal Cancers Symposium ; ;..
84. Weiner LM, Belldegrun AS, Crawford J, et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res. 2008 ; 14: 502-508 (Pubitemid 351226119)
85. Stephenson JJ, Gregory C, Burris H, et al. An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors. Clin Colorectal Cancer. 2009 ; 8: 29-37
86. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004 ; 22: 3003-3015 (Pubitemid 41103711)
87. Howard L, Bullock K, Bendell J, et al. Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
88. Van Cutsem E, Elez E, Stephenson J, et al. Phase Ib results of a multipart trial of AMG 102 plus panitumumab (pmab) in patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC). Proceedings of the 2010 Gastrointestinal Cancers Symposium ; ;..
89. Tebutt NC, Kotasek D, Burris III, et al. Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
90. Peeters M, Infante JR, Rougier P, et al. Phase Ib/II trial of conatumumab and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): safety and efficacy. Proceedings of the 2010 Gastrointestinal Cancers Symposium ; ;..
91. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing 10% epidermal growth factor receptor (EGFr). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
92. Hecht J, Mitchell E, Baranda J, et al. Panitumumab (pmab) efficacy in patients (pts) with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGFr): final efficacy and KRAS analyses. Proceedings of the 2008 Gastrointestinal Cancers Symposium ; ;..
93. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007 ; 110: 980-988 (Pubitemid 47312862)
94. Muro K, Yoshino T, Doi T, et al. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2009 ; 39: 321-326
95. Karthaus M, Letocha H, Greil R, et al. Interim analysis of a single arm, phase II study (20060314) of panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC). Proceedings of the 2009 Gastrointestinal Cancers Symposium ; ;..
96. Cohn A, Smith D, Neubauer M, et al. Effect of tumor KRAS mutation status on second-line treatment with panitumumab (pmab) and FOLFIRI: interim results from the Pmab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment (PRECEPT) study. Proceedings of the 2009 Gastrointestinal Cancers Symposium ; ;..
97. Price T, Peeters M, Douillard J, et al. Safety summary of panitumumab (pmab) in combination with chemotherapy (ctx) from four clinical trials in patients (pts) with metastatic colorectal cancer (mCRC). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
98. Douillard J, Peeters M, Kohne C, et al. Safety of panitumumab (pmab) in combination with chemotherapy (ct) from five clinical trials in 812 patients (pts) with metastatic colorectal cancer (mCRC) and wild-type (WT) KRAS tumors. Proceedings of the 2010 Gastrointestinal Cancers Symposium ; ;..
99. Peeters M, Van Cutsem E, Hecht J, et al. Efficacy and safety of panitumumab across five clinical studies in patients (pts) with metastatic colorectal cancer (mCRC). Proceedings of the 2007 Gastrointestinal Cancers Symposium ; ;..
100. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007 ; 25: 1658-1664 (Pubitemid 46797944)
101. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009 ; 27: 672-680
102. Siena S, Cassidy J, Tabernero J, et al. Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial. Proceedings of the 2010 Gastrointestinal Cancers Symposium ; ;..
103. Peeters M, Price T, Hotko Y, et al. Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). Proceedings of the 2009 ECCO-ESMO Congress ; ;..
104. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005 ; 23: 1803-1810 (Pubitemid 46211358)
105. http://www.nccn.org/professionals/physicians-gls/pdf/colon.pdf. Accessed January 10, 2011.
106. Bokemeyer C, Bondarenko I, Hartmann J, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
107. Punt C, Tol J, Rodenburg C, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
108. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 ; 359: 1757-1765
109. Koza I, Wrba F, Vrbanec D, et al. Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX + C) or FOLFIRI + cetuximab (FF + C): the CECOG/CORE1.2.001 trial. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
110. Amado R, Wolf M, et al. Panitumumab (pmab) efficacy and patient-reported outcomes (PRO) in metastatic colorectal cancer (mCRC) patients (pts) with wild-type (WT) KRAS tumor status. Proceedings of the 2008 Gastrointestinal Cancers Symposium ; ;..
111. Bengala C, Bettelli S, Fontana A, et al. EGFR gene copy number, KRAS and BRAF status, PTEN and AKT expression analysis in patients with metastatic colon cancer treated with anti-EGFR monoclonal antibodies ± chemotherapy. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
112. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008 ; 26: 5705-5712
113. Mitchell E, Hecht J, Baranda J, et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: an updated analysis. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
114. Mitchell E, Lacouture M, Shearer H, et al. Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
115. Shah A, Chen E, Jonker D, et al. A phase II clinical trial of nimotuzumab, an EGFR monoclonal antibody, in metastatic colorectal cancer. Proceedings of the 2009 Gastrointestinal Cancers Symposium ; ;..
116. Piperdi B, Mitchell E, Lacouture M, et al. STEPP, an open-label, randomized study of pre-emptive (P) versus reactive skin toxicity (ST) treatment (tx) in metastatic colorectal cancer (mCRC) patients (pts) receiving panitumumab (pmab) + FOLFIRI or irinotecan-based (Iri) chemotherapy (CT) as second-line tx: results by CT and KRAS status. Proceedings of the 2009 Gastrointestinal Cancers Symposium ; ;..
117. Qiu Li, Mao C, Zhang J, et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer. 2010 ;:
118. Douillard J, Siena S, Cassidy J, et al. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. Proceedings of the 2009 ECCO-ESMO Congress ; ;..
119. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010 ; 28: 1254-1261
120. Rougier P, Stroiakovski D, Köhne C, et al. Addition of cetuximab to FOLFIRI in first-line metastatic colorectal cancer (mCRC): updated survival data and influence of KRAS status on outcome in the CRYSTAL study. Proceedings of the 2009 Gastrointestinal Cancers Symposium ; ;..
121. Van Cutsem E, Rougier P, Köhne C, Stroh C, Schlichting M, Bokemeyer C. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status. In Eur J Cancer (suppl), Proceedings of the 2009 ECCO-ESMO congress. 2009 ;:
122. Vale C, Tierney J, Meade A, et al. Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): a systematic review and meta-analysis of randomized controlled trials (RCTs). Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
123. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009 ; 27: 2091-2096
124. Garm Spindler KL, Pallisgaard N, Rasmussen AA, et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol. 2009 ; 20: 879-884
125. Molinari F, Martin V, Saletti P, et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer. 2009 ; 100: 1087-1094
126. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008 ; 13: 1270-1275
127. Loupakis F, Pollina L, Stasi I, et al. Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
128. Italiano A, Fabas T, Keslair F, et al. KRAS mutational status in primary colorectal tumors and matched metastatic sites: implications for treatment with anti-EGFR monclonal antibodies. Proceedings of the 2008 ESMO Congress ; ;..
129. Cremolini C, Loupakis F, Perrone G, et al. BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients. Proceedings of the 2009 ECCO-ESMO Congress ; ;..
130. Tejpar S, De Roock W. PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium. Proceedings of the 2009 ECCO-ESMO Congress ; ;..
131. Tol J, Dijkstra J, Vink-Börger M, et al. BRAF mutation is associated with a decreased outcome in patients (pts) with advanced colorectal cancer (ACC) treated with chemotherapy and bevacizumab with or without cetuximab. Proceedings of the 2009 ECCO-ESMO Congress ; ;..
132. Bokemeyer C, Kohne C, Rougier P, Stroh C, Schlichting M, Van Cutsem E. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. J Clin Oncol. 2010 ; 28: S3506
133. Santini D, Loupakis F, Canestrari E, et al. Correlation of BRAF wild-type status (WT) in primary colorectal tumors with BRAF status in related metastatic sites: implications for treatment with anti-EGFR antibodies. Proceedings of the 2010 Gastrointestinal Cancers Symposium ; ;..
134. Su X, Lacouture ME, Jia Y, Wu S. Risk of high-grade skin rash in cancer patients treated with cetuximab-an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology. 2009 ; 77: 124-133
135. Newman M, Gerami P, Guitart J, et al. Histological differentiation of skin toxicity between cetuximab, erlotinib and panitumumab (single ErbB1) and lapatinib (dual ErbB1/2) epidermal growth factor receptor inhibitors. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
136. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010 ; 28: 1351-1357
137. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007 ; 25: 5390-5396 (Pubitemid 350232214)
138. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008 ; 113: 847-853
139. Ocvirk J, Rebersek M. Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream. Proceedings of the American Society of Clinical Oncology Annual Meeting ; ;..
140. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol. 2009 ; 16: 16-26
141. LaPlant K, George T, Walden E, et al. Prevention of cetuximab hypersensitivity reactions, test dosing, and retreatment. Proceedings of the 2009 Gastrointestinal Cancers Symposium ; ;..
142. Chung K, Fusco A, Park V, Muller R, Saltz L. Evaluation of routine antihistamine premedication after the first 2 doses of cetuximab. Proceedings of the 2007 Gastrointestinal Cancers Symposium ; ;..
143. Rodriguez J, Viudez A, Ponz-Sarvise M, et al. Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab. Crit Rev Oncol Hematol. 2010 ; 74: 193-202
144. Groenestege WM, Thebault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007 ; 117: 2260-2267 (Pubitemid 47219571)
145. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 2007 ; 8: 387-394 (Pubitemid 46621761)
146. Clinical trials search results. National Cancer Institute Web site. http://www.cancer.gov/search/ResultsClinicalTrials.aspx?protocolsearchid= 6579062. Accessed January 10, 2011.
147. Clinical trials search results. National Cancer Institute Web site. http://www.cancer.gov/search/ResultsClinicalTrials.aspx?protocolsearchid= 6691438. Accessed January 10, 2011.
148. Tan B, Zubal B, Hawkins W, et al. Preoperative FOLFOX plus cetuximab or panitumumab therapy for patients with potentially resectable hepatic colorectal metastases. Proceedings of the 2009 Gastrointestinal Cancers Symposium ; ;..